Objective: This experimental study aimed to evaluate the statin-induced hepatotoxicity in albino rats, as well as to compare the potential hepatotoxicity between atorvastatin and simavastatin through evaluation of both biochemical and histopathological parameters. Materials & Methods: 60 male albino rats were used in this study and were equally divided into three groups. The control group received only saline orally, the atorvastatin group which received (80 mg/kg) orally, and the simavastatin group which received simavastatin (80 mg/kg) orally. The study was conducted over a period of 12 weeks and at the end blood samples and liver tissues were obtained for assessment of biochemical markers of the liver and histopathological examination. Results: All the biochemical parameters in the current study showed higher values in the atorvastatin and simvastatin groups compared to the control group with significant probability value. The significance was detected between each of the statin groups and the control group. However no significant difference was found between atorvastatin and simvastatin group. Likewise, histopathological results showed significant hepatic injury in case of both statin groups compared to the control one. Conclusion & Recommendations: Atorvastatin and simvastatin induced hepatic injury as demonstrated by both biochemical and histopathological results in this study. Moreover, no significant difference was found between atorvastatin and simvastatin as regard statin induced liver injury.
INTRODUCTION
Drug induced liver injury (DILI) refers to liver affection which is usually due to an adverse reaction caused by drugs administration or dietary supplements. DILI generally is considered as a significant cause of potentially severe acute and chronic liver affection (Fontana et al., 2010).
Among the most commonly and widely used drugs all over the world to lower the blood cholesterol levels are statins. Some adverse effects may present with the use of statins despite that they are considered as well tolerated drugs (Björnsson et al., 2013). Myopathy, increased incidence of diabetes and increased levels of serum transaminases are among the most common reported adverse effects of statins (Desai et al., 2014).
Patients with high cholesterol levels are more liable to develop severe vascular and cardiac diseases. These patients are usually prescribed atorvastatin, simvastatin or another one of the statin drugs at a high dose. Usually atorvastatin is the most commonly described drug in such case. This is attributed to the more effective potential of atorvastaatin than simvastatin at lowering blood cholesterol levels (Nawrocki et al., 1995; and Jones et al., 1998). 
Many investigations have recently

MATERIALS & METHODS

Experimental condition
All the experimental animals used in this study received humane care according to the guidelines outlined in the "Guide for the Care and Use of Laboratory Animals" by the National Institute of Health (NIH). The experimental protocol for the use of live animals in this study was approved by Louisiana State University Institutional Animal Care and Use Committee.
Sixty male, albino rats, weighing of 180-200 gm aged 3 months were provided from animal laboratory and used in this experiment. All animals maintained at a constant temperature (25 +/-3 °C) in a controlled room in which a light/dark cycle was maintained. All the rats had free access to water and were fed with standard commercial chow diet. After 7 days of acclimatization, the animals were distributed randomly into three groups each consisted of twenty rats: 3. Estimation of total serum bilirubin was determined by colorimetric methods using commercial kits (DiaSysHolzheim, Germany), on a semiautomatic clinical chemistry analyser.
 Histopathological analysis Liver tissue samples were fixed in 10% buffered formalin, embedded in paraffin and then cut at 4-5 microns thickness. The cut sections were then stained with hematoxylin and eosin (HE) to be examined by light microscopy. Histopathological changes were diagnosed in a blinded manner by a specialized pathologist unaware of the study groups.
 Statistical analysis The collected data were tabulated and analyzed using SPSS version 22 soft ware (SPSS Inc, Chicago, ILL Company). Categorical data were presented as number and percentages while quantitative data were expressed as mean ± standard deviation. Fisher's exact test and ANOVA was used as tests of significance. Significant ANOVA were followed by post -hoc test to detect significant pairs. The accepted level of significance in this work was stated at 0.05 (P <0.05 was considered significant).
RESULTS
 Biochemical results
The mean value±SD for the total serum bilirubin in the control group was 1.2.5±0.12 while in the atorvastatin and simvastatin groups, it was 1.5±0.4 & 1.5±0.3 respectively. The probability value was found highly significant (P= 0.004). This significance was further studied by post-hoc test and the significance was found between each of atorvastatin & simvastatin groups on one hand and the control group on the other hand (P = 0.005 and 0.03 respectively) as shown in table 1.
The mean value±SD for the serum aspartate transaminase (AST) activity in the control group was 70.8±8.4 while in the atorvastatin and simvastatin groups, it was 122.2±60.4 & 111±57.9 respectively. The probability value was found highly significant (P= 0.003) and this significance was further studied by post-hoc test. The significance was found between atorvastatin group and control group (P = 0.003) and also between simvastatin group and the control group (P = 0.02) as shown in table 2.
As for the serum alanine transaminase (ALT) activity, the mean value±SD for the control group was 56.5±7.9. While it was 95.7±36.7 for atrovastatin group and 86.2±30.9 for simvastatin group. The probability value was found highly significant (P= 0.000).
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This significance was further studied by post-hoc test. The significance was found between atorvastatin group and control group (P = 0.000) and also between simvastatin group and the control group (P = 0.001) as shown in table 3. Furthermore, the serum alkaline phosphatase (ALP) activity showed 93.8±7 as a mean value±SD. Atovastatin group has a mean value±SD of 156.5±74.7 compared to simvastatin group which has 136.2±61.6 as a mean value±SD. The probability value was found highly significant (P= 0.003). This significance was further studied by posthoc test while revealed a significance between atorvastatin group and control group (P = 0.004) and also between simvastatin group and the control group (P = 0.02) as shown in table 4.
 Histopathological results Examination of the liver tissue sections in the control revealed that all the cases i.e. 20 samples showed normal hepatic structure. As for the cases treated with atorvastatin, 4 cases (25%) showed hepatocellular injury, 2 cases (10%) showed cholestatic injury of the liver while one case only showed mixed hepatocellular and cholestatic hepatic injury (5%). On the other hand, cases treated with simvastatin were associated with 4 cases (20%) with hepatocellular injury, one case (5%) with cholestatic hepatic injury and also one case (5%) with mixed hepatocellular and cholestatic hepatic injury. The probability was found highly significant (P˂0.007) between the control group and both atorvastatin & simvastatin groups. (table5). However, the use of statins is limited by its adverse effects in many patients and sometimes discontinuation of statins is considered in some patients. Myopathy which may be associated with muscle complaints and increased muscle enzymes has been recorded It has been reported that statins induce elevation of the hepatic liver enzymes that can be used to monitor SILI. The statin-induced elevation of serum hepatic transaminases and serum alkaline phosphatase enzymes usually occurs within the first three to twelve months after introduction of statin therapy (Björnsson et al., 2012; and Russo et al., 2014).
All the biochemical parameters in this study such as total serum bilirubin, serum aspartate transaminase activity, serum alanine transaminase, and serum alkaline phosphatase activity exhibited a higher significant values in the both atorvastatin and simvastatin groups compared to the control group denoting that statins drugs are associated with hepatic injury. These results were in concordance with the study carried by Emilia et al., 2014 showed that atrovastatin is associated with greater incidence of SILI than simvastatin. The incidence of SILI was 6.5% for high dose of atorvastatin while it was 1.3% for simvastatin.
In the current study, it was found that hepatocellular damage is the predominant liver injury in both atorvastatin and simvastatin groups. This result was in concordance with the study carried by Emilia et al., 2014 that described hepatocellular damage as the major hepatic injury in both atorvastatin and simvastatin. Moreover, similar results were reported by Wang et al., 2016 that demonstrated that hepatocellular damage is the predominant liver injury in SILI.
CONCLUSION
The present study demonstrated that statins are associated with a risk of hepatic injury as shown by both biochemical and histopathological results. However, no significant difference was found between either atorvastatin or simvastatin group.
RECOMMENDATIONS
 Further studies should be carried on the same atorvastatin and simvastatins but with a lower therapeutic dose (40 mg/kg) and the results should be compared with the current one.
 Similarly, other statin drugs such as lovastatin, paravastatin, rosuvastatin … should be carefully examined for the potential of drug-induced hepatotoxicity.
 It is advised to evaluate statin induced liver injury in patients under treatment with statins after different intervals of administration.
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